Ductal carcinoma in situ: to treat or not to treat, that is the question
2019/07/08 by on behalf of the PRECISION team, Maartje van Seijen, Esther H. Lips +12 · 25 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Breast Cancer Treatment Studies #Cancer Genomics and Diagnostics #Esophageal Cancer Research and Treatment
paper · pdf · doi:10.1038/s41416-019-0478-6
Abstract
Ductal carcinoma in situ (DCIS) now represents 20-25% of all 'breast cancers' consequent upon detection by population-based breast cancer screening programmes. Currently, all DCIS lesions are treated, and treatment comprises either mastectomy or breast-conserving surgery supplemented with radiotherapy. However, most DCIS lesions remain indolent. Difficulty in discerning harmless lesions from potentially invasive ones can lead to overtreatment of this condition in many patients. To counter overtreatment and to transform clinical practice, a global, comprehensive and multidisciplinary collaboration is required. Here we review the incidence of DCIS, the perception of risk for developing invasive breast cancer, the current treatment options and the known molecular aspects of progression. Further research is needed to gain new insights for improved diagnosis and management of DCIS, and this is integrated in the PRECISION (PREvent ductal Carcinoma In Situ Invasive Overtreatment Now) initiative. This international effort will seek to determine which DCISs require treatment and prevent the consequences of overtreatment on the lives of many women affected by DCIS.
Cited by
- Perspectives from the Cancer and Aging Research Group: Caring for the vulnerable older patient with cancer and their caregivers during the COVID-19 crisis in the United States. [europepmc]
- Efficacy of Emu Oil Transfersomes for Local Transdermal Delivery of 4-OH Tamoxifen in the Treatment of Breast Cancer. [europepmc]
- Breast cancers, mammary stem cells, and cancer stem cells, characteristics, and hypotheses. [europepmc]
- Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project. [europepmc]
- Variability in grading of ductal carcinoma in situ among an international group of pathologists. [europepmc]
- Unmasking the immune microecology of ductal carcinoma in situ with deep learning. [europepmc]
- Expression of CCL2/CCR2 signaling proteins in breast carcinoma cells is associated with invasive progression. [europepmc]
- Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. [europepmc]
- Preoperative ultrasound radiomics analysis for expression of multiple molecular biomarkers in mass type of breast ductal carcinoma in situ. [europepmc]
- Metastasis-suppressor NME1 controls the invasive switch of breast cancer by regulating MT1-MMP surface clearance. [europepmc]
- Multi-Omics Marker Analysis Enables Early Prediction of Breast Tumor Progression. [europepmc]
- Single-cell evaluation reveals shifts in the tumor-immune niches that shape and maintain aggressive lesions in the breast. [europepmc]
- Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines? [europepmc]
- Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study. [europepmc]
- Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort. [europepmc]
- Ductal Carcinoma in Situ: Molecular Changes Accompanying Disease Progression. [europepmc]
- Mechanostimulation of breast myoepithelial cells induces functional changes associated with DCIS progression to invasion. [europepmc]
- The DARC Side of Inflamm-Aging: Duffy Antigen Receptor for Chemokines (DARC/ACKR1) as a Potential Biomarker of Aging, Immunosenescence, and Breast Oncogenesis among High-Risk Subpopulations. [europepmc]
- Proteomics-Based Identification of Dysregulated Proteins and Biomarker Discovery in Invasive Ductal Carcinoma, the Most Common Breast Cancer Subtype. [europepmc]
- A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression. [europepmc]
- Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial. [europepmc]
- Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study. [europepmc]
- 25 year trends in cancer incidence and mortality among adults aged 35-69 years in the UK, 1993-2018: retrospective secondary analysis. [europepmc]
- Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance. [europepmc]
- The Genomic and Biologic Landscapes of Breast Cancer and Racial Differences. [europepmc]
Related